Archil Jaliashvili: Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared on LinkedIn:
‘‘Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia (SCA)
Hyperhaemolysis syndrome (HHS) remains one of the most fatal complicatios of transfusion in SCA, with rapid destruction of both transfused and autologous RBCs.
Conventional therapies (steroids, IVIG, rituximab, eculizumab) often fail, leaving clinicians with limited options.
Case (Epstein and Hadley, J Clin Pharm Ther)
• 19-year-old male with SCA developed HHS post partial exchange transfusion.
• Hb fell to 4.0 g/dL despite methylprednisolone, darbepoetin, rituximab.
• Severe hemoglobinuria, LDH 7,120 U/L, Coombs negative.
New oxygenation therapeutic Breakthrough:
Hemopure (BHOC – our new gen bio analog)
• Single infusion restored oxygen delivery instantly.
• Clinically, the patient regained energy and responsiveness despite critical Hb.
• Effect lasted ~5 hours.
Bortezomib (26S proteasome inhibitor)
• 1.3 mg/m² SC q72h × 4 doses.
• Downregulated NF-κB–driven macrophage activation and hemolysis.
• Hb rose from 4.0 → 7.0 g/dL, reticulocyte count >20%.
Outcome: Patient stabilized and discharged. No alloantibodies detected later.
Why important:
•Hemopure has demonstrated value as a bridge oxygen carrier when hemoglobin (Hb) levels are critically low.
• Bortezomib represents a novel immune-modulating option in transfusion-refractory hyperhemolytic syndromes (HHS).
• This case supports the expansion of HBOCs in clinical emergencies and the initiation of clinical trials of proteasome inhibitors in hemolytic syndromes.
About future possibility:
Our next-generation bio-similar BHOC can serve as a bridge to recovery.
We believe it can transform the approach to Sickle Cell Anemia (SCA) treatment by providing supportive, low-volume infusion therapy before HbS levels become critical.
Much like insulin regulates blood sugar and HbA1c levels, BHOC can help support and control HbS polymerization level, stabilizing oxygen delivery and patient condition.
Contact us for collaboration or discussion about clinical applications and partnerships.”
Article: Successful management of potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure
Authors: Stacy S. Epstein, Terence J. Hadley
Stay updated with all science in the field of hematology with Hemostasis Today.
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs
-
Mar 17, 2026, 15:50Yogesh Kalkonde: Advancing Sickle Cell Care Through Primary Health Training
-
Mar 17, 2026, 15:49Melissa Hollo: Closing the Gap in Maternal Anemia Care Through HerCare
-
Mar 17, 2026, 15:46Simon Senanu: Rouleaux Formation – When Red Cells Stack Like Coins
-
Mar 17, 2026, 15:45Heghine Khachatryan: Hidden Hematologic Causes of Cryptogenic Stroke
-
Mar 17, 2026, 15:45Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
-
Mar 17, 2026, 15:44Jan Sloves: Venous Phasicity and the Role of IVC Mechanics
-
Mar 17, 2026, 15:43How Clinicians Navigate the Challenge of Balancing Clotting and Bleeding in CAD – Vasculearn Network
-
Mar 17, 2026, 15:41Beverly G. Tchang: Lipid-Lowering Therapy in Women During Pregnancy and Lactation